Last 27 quarters of trend data · Healthcare · Healthcare Providers
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -94.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 8.49 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.52 | 9.75 | 0.87 | 0.53 | 0.64 | 0.62 | 3.99 | 0.21 | 0.06 | 0.06 | 0.09 | 0.31 | 0.44 | 0.31 | 0.13 | 0.16 | 0.49 | 1.42 | 1.52 | 2.46 | 3.26 |
| — | +1465.1% | -78.2% | +151.8% | +991.3% | +908.0% | +4472.4% | -32.1% | -86.7% | -80.3% | -31.4% | +89.6% | -11.6% | -77.9% | -91.6% | -93.4% | -84.8% | -60.0% | -54.0% | -27.2% | +105.6% | |
| P/B Ratio | — | — | — | — | — | — | — | 17.34 | 6.51 | 1.59 | 1.18 | 2.84 | 2.63 | 1.43 | 0.48 | 0.51 | 1.13 | 2.88 | 2.98 | 4.12 | 6.55 |
| — | — | — | — | — | — | — | +510.5% | +147.8% | +11.4% | +144.6% | +461.3% | +132.0% | -50.3% | -83.8% | -87.7% | -82.7% | -81.6% | -77.1% | -70.5% | -40.7% | |
| P/FCF | 11.91 | 97.86 | 12.68 | — | 41.55 | — | — | — | 2.40 | 5.06 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | +1628.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.98 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 15.2% | — | 16.8% | 15.8% | 16.0% | 13.9% | 14.6% | 16.5% | 14.6% | 14.4% | 13.2% | 12.6% | 16.8% | 19.5% | 18.8% | 18.5% | 21.9% | 20.0% | 18.3% | 22.3% | 15.9% |
| — | — | +15.3% | -4.3% | +9.9% | -3.7% | +10.6% | +30.7% | -12.9% | -26.2% | -29.9% | -31.7% | -23.4% | -2.6% | +3.0% | -17.2% | +37.3% | -8.4% | -16.3% | +6.4% | -22.4% | |
| Operating Margin | -7.2% | -1.8% | -2.9% | -4.4% | -4.9% | -5.9% | -9.4% | -9.5% | -11.9% | -13.9% | -16.6% | -19.0% | -17.8% | -17.0% | -18.6% | -43.1% | -35.1% | -30.9% | -30.0% | -33.5% | -78.1% |
| — | +70.2% | +69.4% | +53.5% | +59.1% | +57.5% | +43.6% | +50.0% | +33.2% | +18.3% | +10.8% | +56.0% | +49.2% | +45.1% | +38.0% | -28.8% | +55.0% | -649.6% | -1241.9% | -828.0% | -667.1% | |
| Net Margin | -12.1% | -9.3% | -6.1% | -1.7% | -5.3% | -12.1% | -14.2% | -18.8% | -13.1% | -16.1% | -15.7% | -21.0% | -21.9% | -21.2% | -21.1% | -39.4% | -15.4% | -4.1% | -9.0% | 35.0% | -19.4% |
| — | +23.2% | +57.2% | +91.0% | +59.8% | +25.1% | +9.6% | +10.7% | +39.9% | +24.0% | +25.4% | +46.6% | -41.9% | -416.0% | -135.3% | -212.6% | +20.6% | +27.8% | -239.2% | +1805.4% | -97.3% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | -452.4% | -138.2% | -72.1% | -43.9% | -40.5% | -29.1% | -22.3% | -18.5% | -26.9% | -8.7% | -2.1% | -4.3% | 16.3% | -13.4% |
| — | — | — | — | — | — | — | -1018.3% | -375.0% | -224.1% | -137.9% | -50.4% | -234.0% | -948.1% | -333.1% | -264.7% | +34.9% | +65.1% | -164.8% | +717.0% | -251.6% | |
| ROA | -36.8% | -8.6% | -5.7% | -1.5% | -4.6% | -10.1% | -10.5% | -11.6% | -7.5% | -9.0% | -8.1% | -9.6% | -8.8% | -7.8% | -7.3% | -12.0% | -4.0% | -1.1% | -2.8% | 9.4% | -6.9% |
| — | +14.7% | +46.2% | +87.1% | +38.9% | -12.3% | -30.4% | -21.0% | +14.6% | -15.6% | -10.8% | +20.1% | -118.2% | -588.1% | -164.3% | -227.9% | +41.8% | +66.5% | -175.4% | +834.2% | -112.8% | |
| ROIC | -49.7% | — | -7.2% | -8.7% | -8.8% | — | -12.7% | -10.3% | -10.6% | -9.8% | -10.0% | -10.0% | -7.5% | -6.3% | -6.1% | -12.0% | -9.6% | -12.0% | -20.4% | -60.1% | -198.3% |
| — | — | +43.9% | +15.6% | +17.5% | — | -27.5% | -2.2% | -41.5% | -57.1% | -63.1% | +16.0% | +21.7% | +47.8% | +69.9% | +80.1% | +95.2% | -200.0% | -804.0% | -1461.5% | -6742.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 20.18 | 34.31 | 7.94 | 4.37 | 2.90 | 2.10 | 1.63 | 1.37 | 1.12 | 0.87 | 0.83 | 0.15 | 0.14 | 0.00 |
| — | — | — | — | — | — | — | +595.5% | +1535.0% | +386.2% | +218.1% | +159.5% | +141.9% | +97.0% | +791.3% | +689.9% | +49282.6% | +704.1% | +59.2% | -54.0% | -99.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.59 | 1.11 | 1.36 | 1.47 | 1.59 | 1.68 | 1.62 | 1.79 | 2.15 | 2.49 | 3.31 | 3.08 | 4.12 | 4.71 | 3.11 | 3.95 | 4.37 | 4.37 | 3.11 | 4.44 | 5.17 |
| — | -33.7% | -16.0% | -17.9% | -26.2% | -32.6% | -51.1% | -41.8% | -47.8% | -47.2% | +6.6% | -22.0% | -5.6% | +7.8% | +0.0% | -10.9% | -15.4% | +256.5% | +76.5% | +180.2% | +397.6% | |
| Quick Ratio | 1.35 | 0.82 | 1.15 | 1.17 | 1.35 | 1.39 | 1.37 | 1.59 | 1.96 | 2.27 | 2.99 | 2.83 | 3.73 | 4.34 | 2.74 | 3.61 | 4.06 | 4.07 | 2.87 | 4.19 | 4.95 |
| — | -41.3% | -16.5% | -26.5% | -31.1% | -38.8% | -54.0% | -44.0% | -47.5% | -47.6% | +8.9% | -21.6% | -8.1% | +6.7% | -4.4% | -13.8% | -18.0% | +273.5% | +80.5% | +188.9% | +458.7% | |
| Interest Coverage | -4.39 | -1.64 | -4.27 | -0.29 | -2.92 | -7.60 | -8.17 | -2.52 | -10.29 | -6.24 | -6.31 | -9.02 | -7.93 | -5.15 | -5.57 | -6.04 | -6.46 | -0.80 | -88.92 | 264.05 | -209.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STLN stock.
Starling Oncology, Inc.'s current P/E is -94.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Starling Oncology, Inc.'s current operating margin is -7.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Starling Oncology, Inc.'s business trajectory between earnings reports.